Piramal Pharma Limited has reported a robust start to FY27, featuring a 17% increase in revenue and a significant expansion in EBITDA margins across its core business segments.

Key Takeaways

  • Revenue from operations grew by 17% YoY to ₹2,270 Crores.
  • EBITDA witnessed a massive 72% jump compared to the previous year.
  • EBITDA margin expanded by 400 basis points to 12.5%.
  • Strong performance recorded across CDMO, CHG, and Consumer Healthcare segments.

MUMBAI, India: Piramal Pharma Limited (NSE: PPLPHARMA), a global leader in the pharmaceutical and wellness space, has officially announced its consolidated financial results for the first quarter ended June 30, 2026. The results reflect a period of intense operational execution and strategic growth.

Financial Performance Overview

The company reported a consolidated revenue of ₹2,270 Crores, up from ₹1,934 Crores in the same quarter last year, marking a 17% increase. A standout metric is the EBITDA, which surged by 72% to reach ₹2,85 Crores. This growth was primarily driven by higher capacity utilization and improved pricing discipline.

Particulars (₹ Crores)Q1 FY27Q1 FY26% Change
Revenue from Operations2,2701,93417%
EBITDA28516572%
EBITDA Margin12.5%8.5%+400 bps

Why This Matters

BozokMedia analysis shows that Piramal Pharma's ability to expand margins while simultaneously driving top-line growth is a sign of high-quality management and operational leverage. The successful navigation of inflationary pressures through premiumization and cost optimization sets them apart in the competitive pharma landscape.

The expansion in EBITDA margins suggests that Piramal is effectively translating scale into profitability.

Segment-Wise Highlights

CDMO: Experienced broad-based growth globally, supported by a strengthened commercial team and healthy RFP activity. The company is also expanding its ADC capabilities in the US.
Complex Hospital Generics (CHG): Maintained a dominant 48% value share in the US Sevoflurane market.
Piramal Consumer Healthcare (PCH): Showed remarkable resilience with a 40% growth in e-commerce sales and 23% growth in Power Brands.

Did You Know?: Piramal's Consumer Healthcare 'Power Brands' now contribute a staggering 53% of the total segment sales.

Frequently Asked Questions

1. What was the main driver of EBITDA growth?
The growth was driven by higher capacity utilization, pricing discipline, and operational excellence.

2. How did the consumer healthcare segment perform?
It saw robust growth, particularly in e-commerce (40% growth) and through its Power Brands.